[go: up one dir, main page]

AU5247199A - Targeted alphavirus and alphaviral vectors - Google Patents

Targeted alphavirus and alphaviral vectors Download PDF

Info

Publication number
AU5247199A
AU5247199A AU52471/99A AU5247199A AU5247199A AU 5247199 A AU5247199 A AU 5247199A AU 52471/99 A AU52471/99 A AU 52471/99A AU 5247199 A AU5247199 A AU 5247199A AU 5247199 A AU5247199 A AU 5247199A
Authority
AU
Australia
Prior art keywords
cell
alphavirus
cells
virus
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU52471/99A
Other languages
English (en)
Inventor
Boro Dropulic
Lesia Dropulic
J. Marie Hardwick
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johns Hopkins University
Original Assignee
Johns Hopkins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johns Hopkins University filed Critical Johns Hopkins University
Publication of AU5247199A publication Critical patent/AU5247199A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36141—Use of virus, viral particle or viral elements as a vector
    • C12N2770/36143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36141—Use of virus, viral particle or viral elements as a vector
    • C12N2770/36145—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/40—Vectors comprising a peptide as targeting moiety, e.g. a synthetic peptide, from undefined source
    • C12N2810/405—Vectors comprising RGD peptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
    • C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
    • C12N2810/855—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from receptors; from cell surface antigens; from cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AU52471/99A 1998-07-30 1999-07-30 Targeted alphavirus and alphaviral vectors Abandoned AU5247199A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9513898P 1998-07-30 1998-07-30
US60095138 1998-07-30
PCT/US1999/017345 WO2000011201A1 (fr) 1998-07-30 1999-07-30 Alphavirus cible et vecteurs alphaviraux

Publications (1)

Publication Number Publication Date
AU5247199A true AU5247199A (en) 2000-03-14

Family

ID=22250057

Family Applications (1)

Application Number Title Priority Date Filing Date
AU52471/99A Abandoned AU5247199A (en) 1998-07-30 1999-07-30 Targeted alphavirus and alphaviral vectors

Country Status (7)

Country Link
EP (1) EP1100944A1 (fr)
JP (1) JP2002523053A (fr)
AU (1) AU5247199A (fr)
CA (1) CA2337905A1 (fr)
IL (1) IL141176A0 (fr)
WO (1) WO2000011201A1 (fr)
ZA (1) ZA200104382B (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002010417A2 (fr) * 2000-08-02 2002-02-07 Xencor Procedes et compositions pour la construction et l'utilisation de virus a enveloppe comme particules de presentation
WO2005014017A1 (fr) * 2003-08-08 2005-02-17 Yuji Shino Composition medicinale pour traiter le cancer
WO2014151855A1 (fr) * 2013-03-14 2014-09-25 Inviragen, Inc. Compositions et procédés pour formulations d'alphavirus atténué vivant
CN104814984B (zh) * 2014-08-26 2017-09-15 广州威溶特医药科技有限公司 甲病毒在制备抗肿瘤药物方面的应用
EP3762023A4 (fr) * 2018-03-05 2021-12-29 New York University Induction et amélioration d'une immunité antitumorale impliquant des vecteurs de virus sindbis exprimant des protéines de points de contrôle immunitaires
WO2023230675A1 (fr) * 2022-06-03 2023-12-07 Alphinia Pty Ltd Procédé, utilisation et kit se rapportant à un virus à arn

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5091309A (en) * 1986-01-16 1992-02-25 Washington University Sindbis virus vectors
US5811407A (en) * 1997-02-19 1998-09-22 The University Of North Carolina At Chapel Hill System for the in vivo delivery and expression of heterologous genes in the bone marrow
US6432699B1 (en) * 1997-03-28 2002-08-13 New York University Viral vectors having chimeric envelope proteins containing the IgG-binding domain of protein A
ZA988446B (en) * 1997-09-18 2000-03-22 Res Dev Foundation Production of vaccines using arthropod vectored viruses.

Also Published As

Publication number Publication date
WO2000011201A1 (fr) 2000-03-02
JP2002523053A (ja) 2002-07-30
ZA200104382B (en) 2002-08-28
IL141176A0 (en) 2002-02-10
EP1100944A1 (fr) 2001-05-23
CA2337905A1 (fr) 2000-03-02

Similar Documents

Publication Publication Date Title
US6432699B1 (en) Viral vectors having chimeric envelope proteins containing the IgG-binding domain of protein A
US10570416B2 (en) TC-83-derived alphavirus vectors, particles and methods
JP3946768B2 (ja) アルファウイルスｒｎａレプリコン系
CN101802199B (zh) 用于α病毒结构蛋白表达的无启动子盒
Atkins et al. Therapeutic and prophylactic applications of alphavirus vectors
Quetglas et al. Alphavirus vectors for cancer therapy
Pensiero et al. The Hantaan virus M-segment glycoproteins G1 and G2 can be expressed independently
US6982087B2 (en) Vectors derived from South African Arbovirus No. 86
WO2006031996A2 (fr) Ciblage de virus a l'aide d'une glycoproteine sindbis modifiee
JP2017515509A (ja) ワクチン用途のための高力価ウイルス様ベシクルの進化の方法
Ruiz-Guillen et al. Capsid-deficient alphaviruses generate propagative infectious microvesicles at the plasma membrane
Lundstrom Alphaviruses as expression vectors
AU5247199A (en) Targeted alphavirus and alphaviral vectors
US12414973B2 (en) Antigenically stealthed oncolytic viruses
US7378272B2 (en) Packaging cell lines for the continuous production of alphavirus vectors
US20060099587A1 (en) Alphavirus vectors having attentuated virion structural proteins
Liang et al. Recombinant Sindbis virus expressing functional GFP in the nonstructural protein nsP3
Meruelo et al. Generation of Safe, Targetable Sindbis Vectors That Have the Potential for Direct in vivo Gene Therapy
Lundstrom Virus-based vectors for gene expression in mammalian cells: Semliki Forest virus
WO2000050618A1 (fr) Vecteur viral
Chai Identification of a receptor for an avian retrovirus and characterization of a novel gene delivery vector

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted